- Navigating Your Midlife Crisis: Embracing New Possibilities
- City Raccoons Showing Signs of Domestication
- Mapping the Exposome: Science Broadens Focus to Environmental Disease Triggers
- One Week Less on Social Media Linked to Better Mental Health
- Your Brain Changes in Stages as You Age, Study Finds
- Some Suicide Victims Show No Typical Warning Signs, Study Finds
- ByHeart Formula Faces Lawsuits After Babies Sickened With Botulism
- Switch to Vegan Diet Could Cut Your Greenhouse Gas Emissions in Half
- Regular Bedtime Does Wonders for Blood Pressure
- Dining Alone Could Mean Worse Nutrition for Seniors
First Device Approved to Prevent Migraines

The first device designed to prevent migraine headaches among adults has been approved by the U.S. Food and Drug Administration.
Cefaly is a battery-powered, headband-like device that’s worn across the forehead. It provides mild electrical stimulation to the trigeminal nerve, which has been associated with migraines, the agency said in a news release. The user may feel a tingling or massaging sensation where the applied electrode touches the skin.
This is the first transcutaneous electrical nerve stimulation (TENS) device approved to prevent pain, the FDA said.
Migraines are characterized by intense throbbing on one side of the head, sometimes accompanied by nausea and sensitivity to light and sound. Untreated, the pain lasts four hours to 72 hours. Migraines are three times more common in women than men, the FDA said.
The device is meant to be used only once daily for 20 minutes. It was evaluated in a Belgian study of 67 people who were prone to getting more than two migraines per month. The device, while shown to be effective among some users, did not completely prevent migraines or reduce their intensity, the FDA said.
The most common adverse reactions were not wanting to continue to use the device because of the electrical stimulation feelings, sleepiness and headache, the agency said. No serious side effects were reported.
The device is produced by the Belgian firm STX-Med.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.










